Aktienanalyse zu Black Titan Corp (BTTC)BTTCBlack Titan Corp

Black Titan Corporation is a holding company that operates through its subsidiaries, Titan Pharmaceuticals Inc. (TTNP), and TalenTec Sdn Bhd (TalenTec). TTNP is a pharmaceutical company that was previously developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix that is designed to be administered sub-dermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. TalenTec is a provider of HCM software in Malaysia. It has introduced numerous human capital management (HCM) solutions to that market, such as Oracle PeopleSoft HCM, Oracle PeopleSoft Financials, Sunfish Workplaze HR, DayForce HCM, and MiHCM Cloud, through its holistic, integrated and reliable services. It operates in the Financials sector.

Black Titan Corp is not a good buy right now due to its significant decline in performance and negative financial indicators. The stock price has dropped 76.02% year-to-date, and the RSI is at a very low 6.546, indicating extreme oversold conditions. Additionally, the company's gross margin has decreased to 26.76%, down from 36.90% in the previous year, highlighting deteriorating profitability. The main risk is the negative net margin of -262.14%, which suggests severe financial distress.